Amgen vs Pfizer vs Roche and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Amgen 10.054, Pfizer 15.034, Roche 17.5245, AstraZeneca 15.384.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Amgen, Pfizer, Roche, AstraZeneca.| Metric | Amgen | Pfizer | Roche | AstraZeneca |
|---|---|---|---|---|
| Market Cap | $237.52B | $159.99B | $370.34B | $257.42B |
| Revenue | $10.05B | $15.03B | $35.05B | $15.38B |
| Cost of Revenue | $2.81B | $4.09B | $9.21B | $2.52B |
| Gross Profit | $7.24B | $10.94B | $25.84B | $12.86B |
| Operating Income | $3.51B | $4.71B | $10.90B | $3.16B |
| Net Income | $2.38B | $-246.00M | $7.93B | $2.51B |
| R&D Expense | $1.87B | $2.81B | $8.35B | $4.05B |
| Earnings Per Share | $4.37 | -$0.04 | $1.23 | $1.59 |
| Gross Margin | 72.0% | 72.8% | 73.7% | 83.6% |
| Operating Margin | 35.0% | 31.3% | 31.1% | 20.6% |
| Net Profit Margin | 23.6% | -1.6% | 22.6% | 16.3% |
| Free Cash Flow | $3.49B | $302.00M | $6.46B | $2.13B |
| Cumulative Free Cash Flow | $169.18B | $356.70B | $305.80B | $121.22B |
| Operating Cash Flow | $4.00B | $835.00M | $8.28B | $2.89B |
| Cash & Equivalents | $13.99B | $976.00M | $6.13B | $4.89B |